Table 2.

Treatment-emergent adverse events across all subjects by dosing group

Adverse event, n (%)	Placebo (n = 18)	TAK-063 3 mg (n = 11)	TAK-063 10 mg (n = 11)	TAK-063 30 mg (n = 11)	TAK-063 100 mg (n = 11)	TAK-063 300 mg (n = 11)	TAK-063 1000 mg (n = 11)	TAK-063 Total (n = 66)
Somnolence	0	0	0	4 (36.4)	7 (63.6)	5 (45.5)	6 (54.5)	22 (33.3)
Orthostatic tachycardia	1 (5.6)	2 (18.2)	0	1 (9.1)	2 (18.2)	1 (9.1)	7 (63.6)	13 (19.7)
Orthostatic hypotension	3 (16.7)	0	0	0	1 (9.1)	1 (9.1)	5 (45.5)	7 (10.6)
Vomiting	0	0	0	0	1 (9.1)	1 (9.1)	1 (9.1)	3 (4.5)
Nausea	0	0	0	2 (18.2)	0	0	1 (9.1)	3 (4.5)
Dizziness	0	0	0	1 (9.1)	0	1 (9.1)	1 (9.1)	3 (4.5)
Dysarthria	0	0	0	0	0	0	1 (9.1)	1(1.5)
Headache	2 (11.1)	0	0	0	1 (9.1)	1 (9.1)	0	2 (3.0)
Anxiety	0	0	0	0	0	0	1 (9.1)	1 (1.5)
Hypotension	0	0	0	0	1 (9.1)	0	0	1 (1.5)
Blurred vision	0	0	0	0	0	0	1 (9.1)	1 (1.5)
Epistaxis	0	0	0	1 (9.1)	0	0	0	1 (1.5)
Muscle tightness	0	0	0	1 (9.1)	0	0	0	1 (1.5)